zur Navigation zum Inhalt
Innere Medizin 12. Oktober 2016

Indolent lymphoma at ASH 2015: new treatment approaches

At the last American society of hematology (ASH) meeting new genetic prognostic tools for follicular lymphoma (FL) were presented. Recent clinical data support the potential use of chemotherapy-free combinations in treatment-naïve FL, but potential additive toxicities have to be considered. In relapsed disease the bcl2 inhibitor venetoclax (ABT-199) is very promising in combination with chemo-immunotherapy. Furthermore the concept of CAR-T cell therapy seems to be appropriate in highly refractory disease.

Zu diesem Thema wurden noch keine Kommentare abgegeben.

Mehr zum Thema

<< Seite 1 >>

Medizin heute

Aktuelle Printausgaben